Method of Diagnosing Cancer Based on Med15 And/or Med12

Simple SummaryContent extracted from patent full text and abstract with AI.

The invention provides new methods for diagnosing cancer and determining patient prognosis by detecting the levels of MED15 and/or MED12 proteins or gene expression. These biomarkers are shown to be highly expressed in certain cancers, particularly prostate cancer (including castration-resistant types) and head and neck squamous cell carcinoma, compared to healthy tissue. The invention also covers the use of MED15 and MED12 as targets for new cancer therapies, and includes methods for screening drugs that can inhibit these markers to identify potential treatments.

Use CasesContent extracted from patent full text and abstract with AI.

• Early detection and diagnosis of prostate cancer, including castration-resistant prostate cancer, via measurement of MED15 and/or MED12 levels in tissue or fluids.
• Prognostic evaluation of cancer patients (e.g., predicting outcomes and risk assessment in prostate and head and neck cancers) based on MED15/MED12 expression.
• Development and clinical implementation of targeted therapies that inhibit MED15 and/or MED12 gene expression or protein activity for treating cancer, particularly where these markers are overexpressed.
• High-throughput screening of drug compounds for their ability to reduce MED15 and/or MED12 levels, indicating potential anti-cancer effects.
• Monitoring of therapeutic responses and disease progression in patients undergoing cancer treatment, by tracking changes in MED15 and/or MED12 levels.

BenefitsContent extracted from patent full text and abstract with AI.

• Provides a more sensitive and specific diagnostic and prognostic biomarker compared to existing tests, especially in subtypes of prostate cancer where current markers are unreliable.
• Potential for minimally invasive diagnostics, as MED15 and MED12 levels can be measured from body fluids (e.g., blood tests), reducing the need for biopsies.
• Enables patient stratification for tailored therapies, improving personalized cancer management.
• Identification of new therapeutic targets (MED15 and/or MED12), broadening the options for developing anti-cancer drugs, especially for aggressive or treatment-resistant cancers.
• Supports earlier intervention and more frequent monitoring, which can lead to improved patient outcomes.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to methods of diagnosing cancer, determining the prognosis of a patient diagnosed with cancer and identifying a compound for treatment of cancer, using MED15 and MED12 as markers. Furthermore, the invention relates to compounds for the treatment of cancer and use of MED15and MED12 for diagnosis of cancer or prognosis of a patient suffering from cancer.